The Labor Department Finally Made PBMs Show Their Receipts. The Rebates Were Hiding in Plain Sight the Whole Time.
By Dakota Jones
Newsdesk | Political & Government · Public Policy & Regulatory
**ANCHOR INTRO: ** The Labor Department has finalized a rule requiring certain pharmacy benefit managers to disclose more about how they get paid. Rebates, administrative fees, spread pricing, payments from pharmacies: the compensation flows now have to be visible to the fiduciaries overseeing covered plans.
The important qualification, before anyone starts treating this as a magic wand: the rule requires disclosure. It does not itself require every rebate to be passed through to a plan. That separate requirement arrives later.
This guide walks through what the new rule does, who it covers, when it applies, and what employers should do next. The receipts are finally getting itemized. The fine print still matters.
First, what did the Labor Department actually finalize?
On Monday, November 2, 2026, the Department of Labor’s Employee Benefits Security Administration published a final rule called “Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure.” It appears in the Federal Register as document 2026-22306, at 91 FR 69092, and amends 29 CFR Part 2550.
The rule requires providers of pharmacy benefit management services, and certain affiliated providers of brokerage and consulting services, to disclose compensation information to fiduciaries of large, self-insured group health plans covered by ERISA.
PBMs generally negotiate drug prices, design formularies, the lists of covered drugs, and manage pharmacy networks between employers and drugmakers. Their role is central to employer prescription benefits. So is the question of how they are paid.
The rule covers direct and indirect compensation, including administrative fees, spread pricing, payments from drug manufacturers such as rebates, and payments from pharmacies. It operates through ERISA’s section 408(b)(2) prohibited-transaction exemption. In practical terms, the disclosures are meant to help plan fiduciaries decide whether PBM contracts and compensation are reasonable.
The Department says pharmacy spending is a major driver of employer healthcare costs and is growing faster than medical and surgical spending. When the bills are rising, knowing how the middle of the transaction works is more than a paperwork preference.
“Show your receipts” means more visibility, not a rebate ban
Here’s the distinction worth keeping clear: rebates were not newly invented, and the rule does not declare that every rebate belongs to the plan. The Federal Register explains that manufacturer rebates and the extent to which they are retained or passed through have been addressed through contract terms.
The change is that covered plan fiduciaries must receive more detailed information about the compensation PBMs receive. That can make it easier to examine a contract and assess whether the financial arrangement is reasonable. It does not, by itself, settle every policy argument about drug prices, rebate incentives or who should keep a particular payment.
Spread pricing is another piece of the picture. In plain English, it describes a difference between what a plan is charged and what a pharmacy is paid. The new disclosure requirements bring that type of compensation into view alongside administrative fees and payments from manufacturers and pharmacies. Visibility gives fiduciaries information to evaluate; it does not guarantee a specific price outcome.
That’s the less theatrical, and more useful, verdict. Disclosure is a tool. It is not a promise that pharmacy costs will immediately fall.
Who is covered, and who is not?
The detailed rule applies to large, self-insured ERISA group health plans. It also covers the PBM service providers and certain affiliated brokerage and consulting providers serving those plans.
Fully insured plans are outside this rule’s scope. That does not mean this regulation imposes the same detailed disclosure framework on every employer plan in America. If you are a plan sponsor or fiduciary, the first practical question is whether your plan is self-insured and covered by the rule, not whether your PBM contract has a familiar logo on it.
The rule is directed by section 12 of Executive Order 14273, titled Lowering Drug Prices by Once Again Putting Americans First. Its stated regulatory purpose is to improve employer health plan transparency into PBM compensation.
For employers, benefits teams and fiduciaries (from Washington, D.C., to plan offices across the country) the key is to match the rule to the plan’s actual structure and calendar. “We have a pharmacy benefit” is not the same thing as “this specific rule applies to our plan.”
The dates: don’t mix up the two deadlines
The final rule is effective January 4, 2027. Its requirements apply to plan years beginning on or after July 1, 2027.
A separate set of provisions under the Consolidated Appropriations Act, 2026, takes effect for applicable plan years beginning August 3, 2028. That later framework includes reporting and rebate-remittance requirements. The new Department of Labor rule does not accelerate those separate requirements.
Mayer Brown’s November 2 analysis likewise distinguishes the disclosure rule from the later CAA 2026 provisions. Different legal provisions, different dates, different obligations. One deadline is already plenty to track; no need to combine them into a single imaginary super-deadline.
What fiduciaries can do now
The disclosure framework is designed to support review of PBM compensation and contracts. That means affected plan sponsors and fiduciaries can begin preparing before the rule applies.
- Confirm the plan’s status. Work out whether the plan is large, self-insured and subject to ERISA. If it is fully insured, this final rule is outside its scope.
- Map the compensation streams. Review contracts for administrative fees, manufacturer payments, spread pricing, payments from pharmacies, and indirect compensation.
- Prepare to evaluate the disclosures. The point is not simply to collect documents. Fiduciaries need a process for assessing the reasonableness of both the contract and the compensation.
- Keep the 2028 provisions distinct. Track the separate CAA 2026 reporting and rebate-remittance requirements on their own timeline.
This is not an invitation to assume that a disclosure document automatically proves a contract is reasonable. It gives fiduciaries more information for that assessment. A stack of newly disclosed terms is still a stack of terms that someone has to review.
What this rule does not say
Let’s make the boundaries plain:
- It does not apply its detailed requirements to fully insured plans.
- It does not itself require every rebate to be passed through.
- It does not bring the separate August 2028 CAA 2026 requirements forward.
- It does not promise that disclosure alone will lower prescription drug costs.
The political temptation is to announce a transparency rule as if it has already rewritten the economics of drug benefits. The regulatory text is more specific. It gives covered plan fiduciaries information to assess PBM arrangements under ERISA. That matters. It is also not the same as a universal rebate mandate taking effect today.
FAQ
Does the rule apply to my fully insured plan?
No. Fully insured plans are outside this final rule’s scope.
Does the new rule force PBMs to pass every rebate to the plan?
No. This rule requires disclosure of compensation. The separate CAA 2026 rebate-remittance provisions take effect for applicable plan years beginning August 3, 2028.
When should covered plans prepare?
The rule is effective January 4, 2027, and applies to plan years beginning on or after July 1, 2027. Plan fiduciaries should identify whether they are covered and prepare to evaluate the disclosures.
Why does the rule use ERISA section 408(b)(2)?
The disclosure requirements support the prohibited-transaction exemption for service arrangements. They are intended to help plan fiduciaries assess whether PBM contracts and compensation are reasonable.
Final Thoughts
The Labor Department’s final rule makes PBM compensation more visible to fiduciaries of covered large, self-insured ERISA plans. It covers direct and indirect compensation (including rebates, spread pricing, administrative fees and payments from pharmacies) and gives plan fiduciaries more information for evaluating PBM arrangements.
But don’t skip the fine print: disclosure is not the same as mandatory pass-through, and the separate CAA 2026 reporting and rebate-remittance requirements are not accelerated by this rule. The practical next step is straightforward: confirm whether your plan is covered, map the relevant contract and compensation flows, and prepare to review the disclosures on the rule’s timeline.
For more reporting on government and regulation, visit LD3’s Political & Government newsdesk and Public Policy & Regulatory coverage.
Sources